Skip to main content

Table 6 Candidate features have different expression level between GBM and LGG

From: Identification of potential biomarkers related to glioma survival by gene expression profile analysis

  TCGA GSE16011 GSE4271 GSE4412
GBM LGG GBM LGG GBM LGG GBM LGG
CTSZ/IPO8 + (79.22%) - (65.12%)      + (62.71%) - (80.77%)
EFEMP2/IPO8 + (78.57%) - (89.15%) + (83.02%) - (64.22%)     
EFEMP2/SDHA + (58.44%) - (96.12%) + (52.83%) - (85.32%) + (61.84%) - (83.33%)   
EFEMP2/TBP + (94.16%) - (50.39%) + (81.76%) - (64.22%)    + (79.66%) - (65.38%)
ITGA3/IPO8 + (52.60%) - (88.37%)      + (62.71%) - (92.31%)
ITGA5/IPO8 + (56.49%) - (95.54%) + (60.38%) - (79.82%)     
KDELR2/SDHA + (98.70%) - (70.74%) + (83.02%) - (64.22%)     
LITAF/SDHA + (80.52%) - (79.46%) + (88.68%) - (54.13%)     
MAP 2 K3/TBP + (90.26%) - (63.37%)      + (69.49%) - (61.54%)
MDK/IPO8 + (85.06%) - (87.02%) + (76.73%) - (74.31%)    + (79.66%) - (73.08%)
MICALL2/TBP + (83.77%) - (53.10%) + (81.76%) - (55.96%)     
NRP1/IPO8 + (57.79%) - (92.83%) + (57.86%) - (73.39%) + (86.84%) - (70.83%)   
P4HA2/TBP + (57.79%) - (85.27%) + (62.89%) - (86.24%)     
PDIA4/SDHA + (94.81%) - (75.78%)    + (78.95%) - (70.83%)   
PLAUR/TBP + (71.43%) - (89.73%)      + (67.80%) - (92.31%)
PLOD3/SDHA + (50.09%) - (92.25%) + (84.91%) - (55.96%)     
SERPINE1/IPO8 + (68.18%) - (88.76%) + (67.30%) - (77.98%) + (76.32%) - (70.83%) + (84.75%) - (65.38%)
SERPINE1/TBP + (96.10%) - (60.08%) + (69.18%) - (79.82%)     
SOCS3/IPO8 + (50.65%) - (92.64%)      + (74.58%) - (69.23%)
  1. The positive sign “+” means the expression level of survival-related gene comparing to the control gene (log2 ratio) was higher. The negative sign “-” means the expression level of survival-related gene comparing to the control gene (log2 ratio) was lower. The percentage represents how many patients in GBM or LGG are expressed higher/lower than the control genes